FDA approves HIV treatment for newborns
Study and pharmacokinetic data supported the application.
-
By
-
Kathryn Wighton
-
August 26, 2026
-
Clinical Scorecard: FDA approves HIV treatment for newborns
At a Glance
| Category | Detail |
|---|
| Condition | HIV infection in newborns |
| Key Mechanisms | Dolutegravir in combination with other antiretroviral agents |
| Target Population | Newborns from birth through 4 weeks of age who weigh at least 2 kg |
| Care Setting | Pediatric care for HIV treatment |
Key Highlights
- Dolutegravir approved for newborns to treat HIV infection
- Supported by data from the IMPAACT 2023 study
- Safety profile similar to older pediatric and adult patients
- Monitoring for liver damage and allergic reactions is necessary
- Not substitutable on a milligram-per-milligram basis with other formulations
Guideline-Based Recommendations
Diagnosis
- Assess HIV infection in newborns exposed to HIV-1
Management
- Use dolutegravir in combination with standard-of-care antiretroviral medications
Monitoring & Follow-up
- Monitor for liver damage and serious allergic reactions
Risks
- Risk of immune reconstitution syndrome and drug interactions
Patient & Prescribing Data
Newborns exposed to HIV-1 weighing at least 2 kg
Dolutegravir levels comparable to those in adults; treatment duration up to 6 weeks
Clinical Best Practices
- Inform healthcare provider about all medications before initiating dolutegravir
- Monitor for adverse effects during treatment
Related Resources & Content
